PLX - PLX Stock Earnings: Protalix BioTherapeutics Misses EPS Misses Revenue for Q1 2024
2024-05-10 11:54:27 ET
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Protalix BioTherapeutics (NYSEMKT: PLX ) just reported results for the first quarter of 2024.
- Protalix BioTherapeutics reported earnings per share of -6 cents. This was below the analyst estimate for EPS of -2 cents.
- The company reported revenue of $3.75 million.
- This was 59.26% worse than the analyst estimate for revenue of $9.20 million.
InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com.
More From InvestorPlace
- The #1 AI Investment Might Be This Company You’ve Never Heard Of
- Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
- It doesn’t matter if you have $500 or $5 million. Do this now.
The post PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024 appeared first on InvestorPlace .